Abstract

Parkin-type autosomal recessive juvenile-onset Parkinson’s disease is caused by mutations in the PRKN gene and accounts for 50% of all autosomal recessive Parkinsonism cases. Parkin is a neuroprotective protein that has dual functions as an E3 ligase in the ubiquitin–proteasome system and as a transcriptional repressor of p53. While genomic deletions of PRKN exon 3 disrupt the mRNA reading frame and result in the loss of functional parkin protein, deletions of both exon 3 and 4 maintain the reading frame and are associated with a later onset, milder disease progression, indicating this particular isoform retains some function. Here, we describe in vitro evaluation of antisense oligomers that restore functional parkin expression in cells derived from a Parkinson’s patient carrying a heterozygous PRKN exon 3 deletion, by inducing exon 4 skipping to correct the reading frame. We show that the induced PRKN transcript is translated into a shorter but semi-functional parkin isoform able to be recruited to depolarised mitochondria, and also transcriptionally represses p53 expression. These results support the potential use of antisense oligomers as a disease-modifying treatment for selected pathogenic PRKN mutations.

Highlights

  • Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, affecting approximately 1% of the population over the age of 60 years [1]

  • We examined the potential of Antisense oligonucleotides (AOs)-induced exon skipping as a disease-modifying treatment for Parkin-type autosomal recessive juvenile PD (ARJP) arising from amenable mutations in PRKN

  • The deletion of PRKN exons 3 and 4 leads to a shorter in-frame transcript and an internally truncated parkin protein that preserves most of the functional domains (Figure 1D)

Read more

Summary

Introduction

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, affecting approximately 1% of the population over the age of 60 years [1]. The main neuropathological hallmarks of PD are the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the presence of Lewy body and Lewy neurites (α-synuclein polymers) [2] in the SNpc or other regions of the brain, such as the dorsal motor nucleus of the vagus and locus coeruleus. These disturbances produce a broad spectrum of clinical manifestations, including core motor and nonmotor symptoms. Multiple therapeutic strategies are needed, for targeted precision medicines tailored to each PD subtype or individual

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call